Table 3. Phase II studies of capecitabine + irinotecan as first-line treatment of metastatic colorectal cancer.
| Grade 3/4 events (%) | ||||||
|---|---|---|---|---|---|---|
| Schedule | N | RR (%) | Median TTP (months) | Median OS (months) | Neutropenia | Diarrhoea |
| XELIRI (Bajetta et al, 2004) | 140 | 47a | 8.3b | — | 5 | 36 |
| CAPIRI | 44a | 7.6b | 17 | |||
| XELIRI weekly (Borner et al, 2005) | 75 | 34 | 6.9 | 17.4 | 5 | 34 |
| XELIRI | 35 | 9.2 | 24.7 | 19 | 19 | |
| XELIRI Park et al, 2004) | 39 | 44 | 6.7 | — | 10 | 10 |
| XELIRI (Patt et al, 2007) | 52 | 50 | 7.8 | 16.8 | 25 | 20 |
| XELIRI (Rea et al, 2005) | 57 | 42 | 8.3 | — | 28 | 19 |
| XELIRI (Cartwright et al, 2005) | 49 | 45a | 6.2b | 13.4 | 12 | 20 |
| CAPIRI (Kim et al, 2005) | 47 | 49 | 7.5 | 19.5 | 11 | 24 |
| XELIRI 2-weekly (Choi et al, 2008) | 43 | 51 | 10.0 | 15.0 | 5 | 8 |
| XELIRI 2-weekly (this study) | 53 | 32 | 9.0 | 19.2 | 6 | 15 |
Abbreviations: CAPIRI=capecitabine on days 2–15 + irinotecan on days 1 and 8; OS=overall survival; RR=response rate; TTP=time to progression; XELIRI=capecitabine on days 1–14 + irinotecan on day 1 every 3 weeks; XELIRI weekly=capecitabine on days 1–14 + irinotecan on days 1, 8 and 15 every 3 weeks.
a
RR in evaluable patients.
b
Progression-free survival.